期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

缺氧性肺动脉高压新生儿血清中HIF-1α、EPO和ET-1变化测定 被引量：5

暂未订购
导出
摘要 目的探讨缺氧性肺动脉高压新生儿血清中缺氧诱导因子-1α（HIF-1α）、促红细胞生成素（EPO）、血管收缩因子内皮素-1（ET-1）的变化及其临床意义。方法纳入对象为某医院产科在2012年4月至11月间出生的新生儿，在出生24h后，无创监测其肺动脉收缩压（PASP），根据肺动脉收缩压情况分别纳入正常组和轻、中、重度肺动脉高压组，酶联免疫聚合法检测新生儿血清中HIF-1α、EPO、ET-1的水平，对计量资料进行独立样本t检验。结果本实验共纳入新生儿76例，肺动脉压正常组40例，轻、中、重度肺动脉高压组各12例。与正常肺动脉压组比，肺动脉高压组中三者水平均有显著性升高（P〈0．01）；肺动脉高压组问差异也有显著性，血清HIF-1、EPO、以及ET-1的水平随着PASP程度增加而递增（P〈0．01，P〈0．05）。结论在新生儿发生缺氧性肺动脉高压时，血清中HIF-1仅、EPO、Err-1水平显著性上调，且与PASP存在相关性。HIF-1α、EPO、ET-1α参与了HPH的发生。
作者 蔡彬媚 陈敬国
机构地区 中山市医院产科 中山市医院产科新生儿科
出处 《国际医药卫生导报》 2013年第5期605-607,共3页 International Medicine and Health Guidance News
基金 中山市科技攻关计划（20113A129）
关键词 肺动脉高压 缺氧诱导因子-1Α 促红细胞生成素 血管收缩因子内皮素-1
分类号 R722.1 [医药卫生—儿科]
  • 相关文献

参考文献8

  • 1Pate1 R, Aronow WS, Pate1 L, et al. Treatment of pulmonary hypertension [J].Med Sci Monit, 2012, 18(4): RA31-39.
  • 2IVY D. Diagnosis and treatment of severe pediatric pulmonary hypertension [J].Cardiol Rev, 2001, 9(4): 227-237.
  • 3Hu R, Dai A, Tan S. Hypoxia-inducible factor 1 alpha upregulates the expression of inducible nitric oxide synthase gene in pulmonary arterieS of hyposic rat[J].Chin MedJ, 2002, 115(12): 1833-1837.
  • 4Gaine S.Pulmonary Hypertension[J].JAMA, 2000, 284(24) : 3160-3168.
  • 5Compernolle V, Brusselmans K, Acker T, et al. Loss of HIF-2alpha and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice[J].Nat Med, 2002, 8 (7) : 702-710.
  • 6Endo A, Ayusawa M, Minato M, et al. Endogenous nitric oxide and endothelin-1 in persistent pulmonary hypertension of the newborn [J].Eur J Pediatr, 2001, 160(4): 217-222.
  • 7Elvert G, Kappel A, Heideareich R, et al. Cooperative interaction of hypoxia-indueible factor-2alpha (HIF- 2alpha ) and Ets-1 in the transcriptional activation of vascular endothelial growth factor receptor-2 (Flk-1) [J].J BiolChem, 2003, 278(9): 7520-7530.
  • 8杨宁,董俊军,刘克良.内皮素系统在肺动脉高压中的作用[J].国外医学（药学分册）,2005,32(4):222-225. 被引量：2

二级参考文献19

  • 1Schmitz-Spanke S, Schipke JD. Potential role of endothelin-1 and endothelin antagonist in cardiovascular diseases[ J]. Basic Res Cardiol,2000, 95(4) :290 - 298.
  • 2Seo B, Oemar BS, Siebenman R, et al. Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels[J]. Circulation, 1994, 89(3): 1203 - 1208.
  • 3Giaid A, Michel RP, Stewart DJ, et al. Expression of endothelin-1 in lungs of patients with cryptogenic fibrosing alveolitis[J]. Lancet,1993, 341(8860): 1550 - 1554.
  • 4Stewart DJ, Levy RD, Cernacek P, et al. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease[ J ] ?Ann Intern Med, 1991, 114(6) :464 - 469.
  • 5Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension[ J].N Engl J Med, 1993, 328(24) :1732 - 1739.
  • 6Dupuis J, Stewart DJ, Cernacek P, et al. Human pulmonary circulation is an important site for both clearance and production of endothelin-l[J]. Circulation, 1996, 94(7):1578 - 1584.
  • 7Ivy DD, Yanagisawa M, Gariepy CE, et al. Exaggerated hypoxic pulmonary hypertension in endothelin B receptor-deficient rats [J].Am J Physiol Lung Cell Mol Physiol, 2002, 282(4) :L703 - L712.
  • 8Nishida M, Eshiro K, Okada Y, et al. Roles of endothelin ETA and ETB receptors in the pathogenesis of monocrotaline-induced pulmonary hypertension[J]. J Cardiovasc Pharmacol , 2004, 44(2):187- 191.
  • 9Ergul A. Development of endothelin receptor antagonist as potential therapeutic agents[J]. Expert Opin Ther Patent, 2003, 13(1):33-44.
  • 10Prie S, Stewart DJ, Dupuis J. Endothelin A receptor blockade improves nitric oxide-mediated vasodilation in monocrotaline-induced pulmonary hypertension. [J]. Circulation, 1998, 97 ( 21 ): 2169 -2174.

共引文献1

同被引文献52

  • 1金汉珍,黄德珉,官希吉.实用新生儿学[M].3版.北京:人民卫生出版社.2002.
  • 2Rabinovitch M. Molecular pathogenesis of pulmonary arterial hypertension[J]. J Clin Invest, 2008,118 : 2372-2379.
  • 3Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension[J]. Euro Heart, 2009,30(20) : 2493-2537.
  • 4Pan P,Zhang X. Effects of electro acupuncture on endotheli- urn-derived endothelin-1 and endothelial nitric oxide synthe- ses of rats with hypoxia-induced pulmonary hypertension [J]. Exp Boil Med (Maywood), 2010,235 (5) .. 642-648.
  • 5He ZH,Dai AG,Zhang XF,et al. Expressions of hypoxia in ducible factor-1 and inducible nitric oxide synthesis gene in the development of hypoxia pulmonary hypertension in rats [J]. Clin Rehab Tissue Eng Res ,2007,11(36) :7290-7294.
  • 6Brussel Mans K, Compernoll EV, TJ WAM, et al. Heterozy- gous,deficiency of hypoxia-inducible factor-2 alpha protects mice against pulmonary hypertension and right ventricular dysfunction during prolonged hypoxia [J]. J Clin Invest, 2009,111(10) :1519-1527.
  • 7Schiodler MB, Hislop AA, Haworth SG. Porcine pulmonary artery and bronchial responses to endothelin-1 and norepi nephrine on recovery from hypoxic pulmonary hypertension [J]. Pediatr Res ,2006,60(1) :71- 76.
  • 8Yan LD, Kong LL, Yong ZH, et al. Inhibition of endothelin 1 and hypoxia-induced pulmonary presser responses in the rat by a novel selective endothelia A receptor antagonist,di- n-butylaminocarbamyl L-leucyl-Dtryptophanyl D-4 chloro Phe[J]. J Cardiovascular Pharmacol, 2010, 56 (3): 246-254.
  • 9Yoshiko Y, Satoshi H, Takeshi H, et al. Erythropoietin re- sponsive sites in normal and malignant human lung tissues [J]. Anant Sci Int ,2010,85:204-213.
  • 10Vaziri ND. Cardiovascular effects of erythropoietin and ane- mia correction [J]. Curr Opin Nephrol H ypertens , 2001, 10: 633-637.

引证文献5

二级引证文献33

国际医药卫生导报
2013年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部